6. Valirx Planning Endometriosis Clinical Test of its Anti-Cell Growth Candidate, VAL201
Valirx plc, a London-based biopharmaceutical company specializing in oncology therapeutics and diagnostics with a particular focus on cancer treatments and associated biomarkers, is conducting a Phase 1/2 clinical trial of its drug candidate VAL201 on people with hormone-resistant prostate cancer. But the company may soon expand its VAL201 research to endometriosis.